Numerai GP LLC Has $2.27 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Numerai GP LLC increased its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 66.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,792 shares of the company's stock after buying an additional 63,176 shares during the period. Numerai GP LLC owned 0.13% of 10x Genomics worth $2,266,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TXG. Barclays PLC raised its position in shares of 10x Genomics by 11.7% in the third quarter. Barclays PLC now owns 602,536 shares of the company's stock valued at $13,605,000 after buying an additional 63,079 shares in the last quarter. JPMorgan Chase & Co. raised its position in 10x Genomics by 355.0% during the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after purchasing an additional 277,355 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in 10x Genomics during the fourth quarter valued at approximately $26,308,000. Mirador Capital Partners LP raised its position in 10x Genomics by 39.2% during the fourth quarter. Mirador Capital Partners LP now owns 80,983 shares of the company's stock valued at $1,163,000 after purchasing an additional 22,792 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in 10x Genomics during the fourth quarter valued at approximately $945,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Price Performance

Shares of 10x Genomics stock traded up $0.19 during trading on Friday, hitting $9.39. The company's stock had a trading volume of 3,013,323 shares, compared to its average volume of 2,364,889. 10x Genomics, Inc. has a 52 week low of $6.78 and a 52 week high of $25.65. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -6.18 and a beta of 1.94. The stock has a 50-day moving average price of $8.77 and a two-hundred day moving average price of $12.36.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. The business had revenue of $154.88 million for the quarter, compared to analysts' expectations of $131.91 million. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business's quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. On average, equities analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In related news, Director Alan Mateo acquired 40,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were purchased at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares of the company's stock, valued at approximately $687,237.74. This trade represents a 184.41% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the transaction, the chief executive officer now owns 879,482 shares in the company, valued at $9,735,865.74. This represents a 0.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 9.39% of the company's stock.

Analyst Ratings Changes

TXG has been the subject of several research analyst reports. Citigroup lowered their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. The Goldman Sachs Group lowered their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a research report on Monday. Barclays decreased their target price on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, May 10th. Finally, Stephens reaffirmed an "overweight" rating and set a $14.00 target price on shares of 10x Genomics in a research note on Thursday. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, 10x Genomics presently has an average rating of "Hold" and a consensus target price of $16.42.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.